Home / Biotechnology / Global Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies And Forecasts, 2017 To 2025

Global Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies And Forecasts, 2017 To 2025

Published: Jun 2015 | Published By: Acute Market Research

Pharmacogenomics Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2026, the global pharmacogenomics market was valued at US$ 79,70.3 Mn in 2017, and is expected to reach US$ 18,624.5 Mn by 2025, expanding at a CAGR of 5.6% from 2017 to 2025.

Market Insights

Pharmacogenomics or personalized medicine is defined as “the tailoring of medical treatment to the specific characteristics of each patient.” This concept in reality involves the ability to classify individuals into subpopulations that are uniquely or disproportionately susceptible to a particular disease or responsive to a specific treatment. Personalized medicine emphasizes on paradigm shift in medicine from reaction to prevention. The individual response to the drug varies according to the genetic composition. Most of the responses are positive and show improvement while few face the side effects. To address those variations, it is necessary to study how the drug processing is affected by the genes. So when the genetic variation is affecting the drug processing and response, there is scope of the clinical study to be conducted and based on the result, adjust the dosage or to find a different drug according to the genetic composition of an individual.

Genetic study of an individual helps in predicting the susceptibility to disease, its progression and overall improves the diseases detection. Able to design unique disease prevention strategies, prescribe more effective drugs and reduce the ADR’s, enhance quality of life, increase patient compliance; therefore able to optimize the health care cost by reducing the time, cost and rate of failure of clinical trials. Personalized medicine incorporates strong fundamental knowledge about the molecular and genetic frame, which is the main driver for its proliferation.

The global pharmacogenomics market is segmented based on technology type as microarray, sequencing, polymerase chain reaction and other technologies. Sequencing dominates the market, especially with the advent of next generation sequencing attributed by high throughput screening, high accuracy and speed. Further elucidation of this market in terms of technologies is as follows:

• Microarray
• Sequencing
o Sanger Sequencing
o Pyrosequencing
o Next-Generation Sequencing
• Polymerase Chain Reaction
• Other Technologies
o Mass Spectrometry
o Electrophoresis

The global pharmacogenomics market is further segmented in terms of therapeutic application such as oncology, cardiology, psychiatry, infectious diseases, pain management, neurological disorders and others. Among these, oncology segment dominates the therapeutic market followed by psychiatry and infectious diseases.
Currently, North America occupies the largest revenue share for global pharmacogenomics market, largely dominated by the U.S. Major growth drivers of North America market are presence of extensive and evolved healthcare infrastructure, increasing preference for better, cost effective and personalized therapeutics for various diseases and infections. Asia Pacific is expected to be the most attractive regional market and is anticipated to witness extensive growth during the forecast period.

Market Competition Assessment:

Key players in the Pharmcogenomicsmarket are Abbott Laboratories, Inc., Affymetrix, Inc., AstraZeneca plc, Assurex Health, Bayer AG, GeneDX, F. Hoffmann-La Roche Ltd., Illumina, Inc., Myriad Genetics, Inc., Merck & Co, GE Healthcare, GlaxoSmithKline, Johnson & Johnson, Pfizer, Inc., Pathway Genomics, Qiagen, Inc., Teva Pharmaceutical Industries Ltd, Thermo Fisher Scientific, Transgenomic, Inc.

Key Market Movements:

• Focus on personalized medicine emphasizing on the paradigm shift in medicine from reaction to prevention. Able to design unique disease prevention strategies, prescribe more effective drugs and reduce the ADR’s, enhance quality of life, increase patient compliance.
• Recently, pharmacogenomics have being extensively used in drug development. It is used at various stages of drug development assessing and identifying effect of drug target polymorphisms on drug response.
• Discovery of new biological mechanisms and identification of molecules with improved efficacy and safety

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Pharmacogenomics Market Portraiture
2.2 Global Pharmacogenomics Market Share, by Technology type, 2015 (US$ Mn)
2.3 Global Pharmacogenomics Market Share, by Application type, 2015 (US$ Mn)
2.4 Global Pharmacogenomics Market, by Geography, 2015 (Value %)

Chapter 3 Global Pharmacogenomics Market Analysis
3.1 Global Pharmacogenomics Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Rise in investment in research and development
3.3.1.2 Advancement in technology pharmacogenomics engineering to create in vivo environment
3.3.2 Challenges
3.3.2.1 Lack of consistency in pharmacogenomics products
3.3.3 Opportunities
3.3.3.1 Focus on regenerative medicine
3.3.3.2 Increased awareness of organ transplantation
3.4 Attractive Investment Proposition, 2015
3.5 Market Positioning of Key Players in Pharmacogenomics

Chapter 4 Global Pharmacogenomics Market Analysis, by Technology Type, 2014-2024 (US$ Mn)
4.1 Introduction
4.2 Microarray
4.3 Sequencing
4.3.1 Sanger Sequencing
4.3.2 Pyrosequencing
4.3.3 Next-Generation Sequencing
4.4 Polymerase Chain Reaction
4.5 Other Technologies
4.5.1 Mass Spectrometry
4.5.2 Electrophoresis

Chapter 5 Global Pharmacogenomics Market Analysis, by Application Type, 2014-2024 (US$ Mn)
5.1 Introduction
5.2 Oncology
5.3 Cardiology
5.4 Pain Management
5.5 Neurological Disorders
5.6 Other Applications

Chapter 6 Global Pharmacogenomics Market, by Geography
6.1 Preface
6.2 North America (U.S. & Canada)
6.3 Europe (U.K., Germany & Rest of Europe)
6.4 Asia Pacific (China, Japan, and Rest of APAC)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 7 Company Profiles
7.1 Abbott Laboratories, Inc.
7.2 Affymetrix, Inc.
7.3 AstraZeneca plc
7.4 Assurex Health
7.5 Bayer AG
7.6 GeneDX
7.7 F. Hoffmann-La Roche Ltd.
7.8 Illumina, Inc
7.9 Myriad Genetics, Inc
7.10 Merck & Co
7.11 GE Healthcare
7.12 GlaxoSmithKline
7.13 Johnson & Johnson
7.14 Pfizer, Inc.
7.15 Pathway Genomics
7.16 Qiagen, Inc.
7.17 Teva Pharmaceutical Industries Ltd
7.18 Thermo Fisher Scientific
7.19 Transgenomic, Inc.
7.20 Other Notable Players

TABLE 1 Global Pharmacogenomics Market, By Technology Type 2015 - 2025 (US$ Mn)
TABLE 2 Global Sequencing Market, By Technology Type 2015 - 2025 (US$ Mn)
TABLE 3 Global Pharmacogenomics Market, By Application Type 2015 - 2025 (US$ Mn)
TABLE 4 Global Pharmacogenomics Market, by Geography, 2015 - 2025 (US$ Mn)
TABLE 5 North America Pharmacogenomics Market, by Country, 2015 - 2025 (US$ Mn)
TABLE 6 Europe Pharmacogenomics Market, by Country, 2015 - 2025 (US$ Mn)
TABLE 7 Asia-Pacific Pharmacogenomics Market, by Country, 2015 - 2025 (US$ Mn)
TABLE 8 Latin America Pharmacogenomics Market, by Country, 2015 - 2025 (US$ Mn)
TABLE 9 Middle East and Africa Pharmacogenomics Market, by Country, 2015 - 2025 (US$ Mn)
TABLE 10 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 11 Affymetrix, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 12 AstraZeneca plc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 13 Assurex Health: Company Snapshot (Business Description; Financial Performance; Product Position Portfolio; News Coverage)
TABLE 14 C Bayer AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 15 GeneDX: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 C B F. Hoffmann-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Illumina, Inc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Myriad Genetics, Inc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Merck & Co: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 GE Healthcare: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 21 GlaxoSmithKline: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 22 Johnson & Johnson: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 23 Pfizer, Inc. : Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 24 Pathway Genomics : Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 25 Qiagen, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 26 Teva Pharmaceutical Industries Ltd: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 27 Thermo Fisher Scientific: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 28 Transgenomic, Inc.s: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)

FIG. 1 Global Pharmacogenomics Market: Research Methodology
FIG. 2 Global Pharmacogenomics Market Share, by Technology type, 2015 (US$ Mn)
FIG. 3 Global Pharmacogenomics Market Share, by Application type, 2015 (US$ Mn)
FIG. 4 Global Pharmacogenomics Market, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition: Global Pharmacogenomics Market, by Geography
FIG. 6 Market Positioning of Key Players in Pharmacogenomics
FIG. 7 Global Microarray Market in Pharmacogenomics, 2015 - 2025 (US$ Mn )
FIG. 8 Global Sanger Sequencing Market in Pharmacogenomics, 2015 - 2025 (US$ Mn)
FIG. 9 Global Pyrosequencing Market in Pharmacogenomics, 2015 - 2025 (US$ Mn )
FIG. 10 Global Next-Generation Sequencing Market in Pharmacogenomics, 2015 - 2025 (US$ Mn )
FIG. 11 Global Polymerase Chain Reaction sMarket in Pharmacogenomics, 2015 - 2025 (US$ Mn )
FIG. 12 Global Other Technologies Market in Pharmacogenomics, 2015 - 2025 (US$ Mn)
FIG. 13 Global Mass Spectrometry Market in Pharmacogenomics, 2015 - 2025 (US$ Mn)
FIG. 14 Global Electrophoresis Market in Pharmacogenomics, 2015 - 2025 (US$ Mn )
FIG. 15 Global Oncology Market in Pharmacogenomics, 2015 - 2025 (US$ Mn )
FIG. 16 Global Cardiology Market in Pharmacogenomics, 2015 - 2025 (US$ Mn)
FIG. 17 Global Pain Management Market in Pharmacogenomics, 2015 - 2025 (US$ Mn)
FIG. 18 Global Neurological Disorders Market in Pharmacogenomics, 2015 - 2025 (US$ Mn)
FIG. 19 Global Other Application Market in Pharmacogenomics, 2015 - 2025 (US$ Mn)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +